Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency (REAL-LAUGH)

November 10, 2026 updated by: Fundació Sant Joan de Déu

The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.

Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.

Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.

Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Marta Ramon Krauel, MD PhD
  • Phone Number: 71702 +34 932 804 000
  • Email: marta.ramon@sjd.es

Study Locations

      • Santiago de Compostela, Spain
    • Barcelona
      • Barcelona, Barcelona, Spain, 08950
        • Hospital Sant Joan de Déu
        • Contact:
          • Marta Ramon Krauel, MD PhD
          • Phone Number: 71702 +34 932 804 000
          • Email: marta.ramon@sjd.es
    • Madrid
    • Valencia
      • Valencia, Valencia, Spain
    • Zaragoza
      • Zaragoza, Zaragoza, Spain
        • Hospital Universitario Miguel Servet
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 16 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.

Description

Inclusion Criteria:

  • Age between 3 and 16 years.
  • Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
  • Growth hormone treatment approved by the relevant local authorities and institution.
  • Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.

Exclusion Criteria:

- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Weekly Long-Acting Growth Hormone

Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

Other Names:
  • Somatrogon
  • NGENLA
Daily Recombinant Human Growth Hormone

Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

Other Names:
  • Somatropin
  • Norditropin
  • Omnitrope
  • Genotonorm

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Percentage Total Body Fat
Time Frame: Baseline and 12 months

Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated.

Baseline and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Lean Body Mass
Time Frame: Baseline and 12 months

Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms.

Baseline and 12 months
Change in body mass index standard deviation score (BMI-SDS)
Time Frame: Baseline and 12 months

Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in height standard deviation score (SDS)
Time Frame: Baseline and 12 months

Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in Waist Circumference
Time Frame: Baseline and 12 months

Change in waist circumference from baseline to 12 months, expressed in centimeters.

Baseline and 12 months
Change in Waist-to-Hip Ratio
Time Frame: Baseline and 12 months

Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless.

Baseline and 12 months
Change in Systolic Blood Pressure
Time Frame: Baseline and 12 months

Change in systolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Diastolic Blood Pressure
Time Frame: Baseline and 12 months

Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Fasting Glucose Concentration
Time Frame: Baseline and 12 months

Change in fasting blood glucose concentration from baseline to 12 months.

Baseline and 12 months
Change in Fasting Insulin Concentration
Time Frame: Baseline and 12 months

Change in fasting blood insulin concentration from baseline to 12 months.

Baseline and 12 months
Change in HOMA-IR
Time Frame: Baseline and 12 months

Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months.

Baseline and 12 months
Change in Total Cholesterol Concentration
Time Frame: Baseline and 12 months

Change in total cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in LDL Cholesterol Concentration
Time Frame: Baseline and 12 months

Change in LDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in HDL Cholesterol Concentration
Time Frame: Baseline and 12 months

Change in HDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in Triglyceride Concentration
Time Frame: Baseline and 12 months

Change in Triglyceride concentration from baseline to 12 months.

Baseline and 12 months
Change in Change in Carotid Intima-Media Thickness
Time Frame: Baseline and 12 months

Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters.

Baseline and 12 months
Change in Bone Mineral Density Z-Score
Time Frame: Baseline and 12 months

Change in bone mineral density Z-score measured by DXA from baseline to 12 months.

Baseline and 12 months
Change in Height Standard Deviation Score
Time Frame: Baseline and 12 months

Change in height standard deviation score (height SDS) from baseline to 12 months.

Baseline and 12 months
Change in Growth Velocity Standard Deviation Score
Time Frame: Baseline and 12 months

Change in growth velocity standard deviation score from baseline to 12 months.

Baseline and 12 months
Change in Bone Age Minus Chronological Age
Time Frame: Baseline and 12 months

Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas.

Baseline and 12 months
Change in IGF-1 standard deviation score
Time Frame: Baseline and 12 months

Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months.

Baseline and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

June 1, 2028

Study Completion (Estimated)

June 1, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • EOM-17-26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.